The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...

Trodelvy/Keytruda patients had 11.2 months progression-free survival vs 7.8 months for chemotherapy/Keytruda ASCO says Trodelvy/Keytruda likely to become standard of care Patients still being ...